Autism Awareness Month has highlighted not only the social and emotional aspects of autism spectrum disorders (ASD), but also the focus on underlying biological mechanisms that influence autism and nervous system conditions. Among the promising areas of research is the role of High-mobility group box 1 (HMGB1) protein, which is gaining attention for its potential as a common biomarker and therapeutic target across various neurological diseases, including autism.
HMGB1 has increasingly been associated with neuroinflammation—a key factor in the pathogenesis of several neurological conditions such as autism: recent studies suggest that HMGB1 may contribute to the chronic state of low-grade inflammation observed in the central nervous system of individuals with autism. Elevated levels of HMGB1 in ASD patients correlate with the severity of symptoms, impacting social interactions and communication.
This link is mediated through the HMGB1/RAGE/TLR4 axis, emphasizing the protein’s role in neuroinflammatory processes that could be central in the onset and progression of autism.
Understanding the molecular interactions of HMGB1 could open new avenues for therapeutic interventions, targeting neuroinflammatory pathways to potentially improve the course of autism.
In HMGBiotech we provide comprehensive information to facilitate informed decision-making for research involving HMGB1.
Contact us for your pre-sales questions about HMGB1
Read the full article about the study:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.1029891/full
